AU566814B2 - Anhydrous stable crystalline s-form of prazosin hydrochloride - Google Patents

Anhydrous stable crystalline s-form of prazosin hydrochloride

Info

Publication number
AU566814B2
AU566814B2 AU34510/84A AU3451084A AU566814B2 AU 566814 B2 AU566814 B2 AU 566814B2 AU 34510/84 A AU34510/84 A AU 34510/84A AU 3451084 A AU3451084 A AU 3451084A AU 566814 B2 AU566814 B2 AU 566814B2
Authority
AU
Australia
Prior art keywords
stable crystalline
prazosin hydrochloride
anhydrous stable
anhydrous
prazosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34510/84A
Other languages
English (en)
Other versions
AU3451084A (en
Inventor
Stig Olof Engelbert Lindholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fermion Oy
Original Assignee
Orion Yhtyma Fermion Oy
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtyma Fermion Oy, Orion Yhtyma Oy filed Critical Orion Yhtyma Fermion Oy
Publication of AU3451084A publication Critical patent/AU3451084A/en
Application granted granted Critical
Publication of AU566814B2 publication Critical patent/AU566814B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU34510/84A 1984-06-25 1984-10-19 Anhydrous stable crystalline s-form of prazosin hydrochloride Ceased AU566814B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI842544A FI79107C (fi) 1984-06-25 1984-06-25 Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
FI842544 1984-06-25

Publications (2)

Publication Number Publication Date
AU3451084A AU3451084A (en) 1986-01-02
AU566814B2 true AU566814B2 (en) 1987-10-29

Family

ID=8519293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34510/84A Ceased AU566814B2 (en) 1984-06-25 1984-10-19 Anhydrous stable crystalline s-form of prazosin hydrochloride

Country Status (17)

Country Link
US (2) US4739055A (enExample)
JP (1) JPS6115881A (enExample)
AT (1) AT389117B (enExample)
AU (1) AU566814B2 (enExample)
BE (1) BE900925A (enExample)
CH (1) CH661045A5 (enExample)
DE (1) DE3429415A1 (enExample)
FI (1) FI79107C (enExample)
FR (1) FR2567124B1 (enExample)
GB (1) GB2160861B (enExample)
IL (1) IL73267A (enExample)
IT (1) IT1224142B (enExample)
LU (1) LU85616A1 (enExample)
NL (1) NL8403250A (enExample)
NZ (1) NZ209962A (enExample)
PT (1) PT79411B (enExample)
ZA (1) ZA85910B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU586318B2 (en) * 1986-03-21 1989-07-06 Heumann Pharma Gmbh & Co. Crystalline, anhydrous ```-form of 2-``4-(2-furoyl)- (2-piperazin)-1-yl``-4-amino-6, 7-dimethoxyquinazoline hydrochloride and a process for its preparation

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2756846B2 (ja) * 1989-12-28 1998-05-25 住化ファインケム株式会社 無水のε型結晶体２―〔４―（２―フロイル）ピペラジン―１―イル〕―４―アミノ―６，７―ジメトキシキナゾリン塩酸塩及びその製造方法
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
SK286975B6 (sk) * 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CA2696579C (en) * 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969375A (en) * 1961-01-24 Certification of correction
DE156532C (enExample) *
BE427505A (enExample) * 1937-05-25
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives
US3433788A (en) * 1966-04-27 1969-03-18 Union Carbide Corp Process for recovery of amines from aqueous solutions by solvent treatment and distillation
US3421983A (en) * 1967-03-07 1969-01-14 Lummus Co Azeotropic distillation of aqueous toluene diamine
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3743672A (en) * 1970-05-27 1973-07-03 Halcon International Inc Separation of water in alkylene glycol mono and diester purification by azeotropic distillation
GB1308718A (en) * 1970-07-01 1973-03-07 Sir Soc Italiana Resine Spa Method of separating vinyl acetate from liquid mixtures
IT956765B (it) * 1972-06-22 1973-10-10 Montedison Spa Procedimento per la purificazione di 1 3 diossolano
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
FI64367C (fi) * 1980-02-26 1986-08-05 Orion Yhtymae Oy Foerfarande foer framstaellning av alfa-form av prazosinhydroklorid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU586318B2 (en) * 1986-03-21 1989-07-06 Heumann Pharma Gmbh & Co. Crystalline, anhydrous ```-form of 2-``4-(2-furoyl)- (2-piperazin)-1-yl``-4-amino-6, 7-dimethoxyquinazoline hydrochloride and a process for its preparation

Also Published As

Publication number Publication date
GB2160861B (en) 1987-11-18
FI79107C (fi) 1989-11-10
ZA85910B (en) 1985-09-25
NZ209962A (en) 1987-06-30
LU85616A1 (fr) 1985-06-04
US4739055A (en) 1988-04-19
CH661045A5 (de) 1987-06-30
IT1224142B (it) 1990-09-26
FI842544A0 (fi) 1984-06-25
JPH0481993B2 (enExample) 1992-12-25
PT79411B (en) 1986-09-15
ATA344184A (de) 1989-03-15
FR2567124B1 (fr) 1990-09-21
IL73267A (en) 1988-06-30
FI842544L (fi) 1985-12-26
AU3451084A (en) 1986-01-02
DE3429415C2 (enExample) 1990-05-03
US4873330A (en) 1989-10-10
FI79107B (fi) 1989-07-31
GB2160861A (en) 1986-01-02
AT389117B (de) 1989-10-25
NL8403250A (nl) 1986-01-16
IT8423292A0 (it) 1984-10-24
IL73267A0 (en) 1985-01-31
PT79411A (en) 1984-11-01
FR2567124A1 (fr) 1986-01-10
BE900925A (fr) 1985-02-15
DE3429415A1 (de) 1986-01-02
GB8424999D0 (en) 1984-11-07
JPS6115881A (ja) 1986-01-23

Similar Documents

Publication Publication Date Title
AU566814B2 (en) Anhydrous stable crystalline s-form of prazosin hydrochloride
AU2595288A (en) New crystalline copolymers of propylene
AU582366B2 (en) Crystalline alpha-maltose
GB8502702D0 (en) Production of seedlings
PL275093A1 (en) Method of manufacture of new crystalline monohydrate 1-carbacephalosporin
AU566679B2 (en) Crystalline aluminosilicophosphate
AU4673685A (en) Derivatives of methylene-bisphosphonic acid
JPS6426560A (en) Novel manufacture of compound
IL87606A0 (en) Crystalline aluminumphosphate compositions
AU1754788A (en) Synthesis of crystalline silicophosphoaluminate
JPS6442481A (en) Novel manufacture of compound
JPS6445710A (en) Crystalline aluminophosphate composition
JPS649990A (en) Novel manufacture of compound
JPS6433010A (en) Manufacture of solution of aluminophosphate crystalline composition
GB8521939D0 (en) Synthesis of crystalline aluminosilicate
DE3568801D1 (en) Growth of single crystal cadmium-indium-telluride
AU580636B2 (en) Crystalline 2-aminomethyl-6-(1-hydroxyethyl)-2-penem-3- carboxylic acid
GB2153700B (en) Crystal growth
NZ214237A (en) Crystalline galloborosilicates
JPS649807A (en) Crystalline aluminophosphate composition
GB8709632D0 (en) Crystalline compounds
PL256939A1 (en) Method of obtaining novel n-substituted acyl-lactam compounds
GB2155916B (en) Crystalline metallophosphates
PH24186A (en) Crystalline form iii of n0(-(((s)-4-oxo-2-azetidinyl)-carbonyl)-l-histidyl-l-prolinamide
AU4194285A (en) N-formyl-dithiophosphonic acid amide derivatives